Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neuronetics, Inc.STIM · Entity 6248 | VP of Prod. Dev. & Operations | March 09, 2021 | March 11, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neuronetics, Inc.
Report date March 09, 2021 · Filed March 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,554 |
Reported balance
After 2021-03-09 transaction · row 1
1 source rowRow 1 · 2021-03-09 · Sale · Disposed 5,524 · Balance 162,554 F1: The sales reported in this Form 4 were non-discretionary sales to satisfy the reporting person's tax withholding obligation upon vesting of a portion of a restricted stock unit award. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $14.12 to $14.99. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were non-discretionary sales to satisfy the reporting person's tax withholding obligation upon vesting of a portion of a restricted stock unit award.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $14.12 to $14.99. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2021 Filed Mar 11, 2021 22:09 UTC | Neuronetics, Inc. STIM · Entity 6248 | SaleCommon Stock | 5,524 | $14.65 | $80,926.60 |
DisclosureSEC source: 0000925421-21-000109 · edgar.xml · nonDerivative · entry 1 Harper Gregory · CIK 0001744952 · VP of Prod. Dev. & Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,554 F1 · shares: The sales reported in this Form 4 were non-discretionary sales to satisfy the reporting person's tax withholding obligation upon vesting of a portion of a restricted stock unit award. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $14.12 to $14.99. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:17 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantPerformance Restricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000925421-21-000075 · edgar.xml · derivative · entry 2 Harper Gregory · CIK 0001744952 · VP of Prod. Dev. & Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents a contingent right to receive one share of the Issuer's common stock. The PRSU rights vest upon the Issuer's common stock achieving a 30 day volume weighted average price of $25 per share. F3 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents a contingent right to receive one share of the Issuer's common stock. The PRSU rights vest upon the Issuer's common stock achieving a 30 day volume weighted average price of $25 per share. F3 · derivative.expiration_date: Each performance restricted stock unit ("PRSU") represents a contingent right to receive one share of the Issuer's common stock. The PRSU rights vest upon the Issuer's common stock achieving a 30 day volume weighted average price of $25 per share. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:17 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 17,085 | $0.00 | $0.00 |
DisclosureSEC source: 0000925421-21-000075 · edgar.xml · nonDerivative · entry 1 Harper Gregory · CIK 0001744952 · VP of Prod. Dev. & Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,078 F1 · shares: Represents a restricted stock unit ("RSU") award that vests in three equal annual installments beginning on February 3, 2022, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 21, 2021 Filed Jan 26, 2021 02:27 UTC | Neuronetics, Inc. STIM · Entity 6248 | SaleCommon Stock | 2,969 | $18.21 | $54,065.49 |
DisclosureSEC source: 0000925421-21-000053 · edgar.xml · nonDerivative · entry 1 Harper Gregory · CIK 0001744952 · VP of Prod. Dev. & Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,993 F1 · shares: The sales reported in this Form 4 were non-discretionary sales to satisfy the reporting person's tax withholding obligation upon vesting of a portion of a restricted stock unit award. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $17.46 to $19.49. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 21:41 UTC | Neuronetics, Inc. STIM · Entity 6248 | Tax withholdingCommon Stock | 1,018 | $2.00 | $2,036.00 |
DisclosureSEC source: 0001192482-20-000220 · edgar.xml · nonDerivative · entry 1 Harper Gregory · CIK 0001744952 · VP of R&D, Ops. and Prod. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,962 F1 · price: Represents the weighted average sale price. The highest price at which shares were sold was $2.00 and the lowest price at which shares were sold was $1.99. The Reporting Person undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 21:51 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 44,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-20-000204 · edgar.xml · nonDerivative · entry 1 Harper Gregory · CIK 0001744952 · VP of R&D, Ops. and Prod. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,980 F1 · shares: Represents a restricted stock unit ("RSU") award of which 1/3 vests on each of the first, second and third anniversaries of the date of grant, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 21:28 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 35,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-004001 · doc4.xml · nonDerivative · entry 1 Harper Gregory · CIK 0001744952 · VP of R&D, Ops. and Prod. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,480 F1 · shares: One-third (1/3rd) of the shares subject to the restricted stock unit ("RSU") grant shall vest on each of January 15, 2021, January 15, 2022 and January 15, 2023, subject to Reporting Person continuing to provide service through each such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:51 UTC | Neuronetics, Inc. STIM · Entity 6248 | PurchaseCommon Stock | 10,000 | $4.40 | $44,000.00 |
DisclosureSEC source: 0001209191-19-061145 · doc4.xml · nonDerivative · entry 1 Harper Gregory · CIK 0001744952 · VP of R&D, Ops. and Prod. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,480 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.39 to $4.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 22:05 UTC | Neuronetics, Inc. STIM · Entity 6248 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 19,213 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001209191-19-043415 · doc4.xml · derivative · entry 2 Harper Gregory · CIK 0001744952 · VP of R&D, Ops. and Prod. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,323 Underlying: Common Stock · 19,213 shares Expires 2026-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vested on September 12, 2017, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 22:05 UTC | Neuronetics, Inc. STIM · Entity 6248 | Exercise / conversionCommon Stock | 19,213 | $3.19 | $61,289.47 |
DisclosureSEC source: 0001209191-19-043415 · doc4.xml · nonDerivative · entry 1 Harper Gregory · CIK 0001744952 · VP of R&D, Ops. and Prod. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 22, 2019 Filed Apr 23, 2019 20:55 UTC | Neuronetics, Inc. STIM · Entity 6248 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001209191-19-025592 · doc4.xml · derivative · entry 2 Harper Gregory · CIK 0001744952 · VP of R&D, Ops. and Prod. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,536 Underlying: Common Stock · 35,000 shares Expires 2026-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vested on September 12, 2017, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| April 22, 2019 Filed Apr 23, 2019 20:55 UTC | Neuronetics, Inc. STIM · Entity 6248 | Exercise / conversionCommon Stock | 35,000 | $3.19 | $111,650.00 |
DisclosureSEC source: 0001209191-19-025592 · doc4.xml · nonDerivative · entry 1 Harper Gregory · CIK 0001744952 · VP of R&D, Ops. and Prod. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 23:13 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantEmployee Stock Option (right to buy) · Derivative | 19,829 | $0.00 Strike: $16.42 | $0.00 |
DisclosureSEC source: 0001209191-19-018612 · doc4.xml · derivative · entry 2 Harper Gregory · CIK 0001744952 · VP of R&D, Ops. and Prod. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,829 Underlying: Common Stock · 19,829 shares Expires 2029-03-08 F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on March 8, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 23:13 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 11,267 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-018612 · doc4.xml · nonDerivative · entry 1 Harper Gregory · CIK 0001744952 · VP of R&D, Ops. and Prod. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,267 F1 · shares: Twenty-five percent (25%) of the shares subject to the restricted stock unit ("RSU") grant shall vest on each of March 8, 2020 and March 8, 2021, and fifty percent (50%) of the shares subject to the RSU grant shall vest on March 8, 2022, subject to Reporting Person continuing to provide service through each such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.